Drug intelligence / Profile preview

VX-A903-1

Development stage: Preclinical
Lead developer: VERAXA Biotech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

VX-A903-1 is an early-stage bispecific T-cell engager (BiTAC-TCE) being developed by VERAXA Biotech for the treatment of solid tumors, including lung cancer, colon cancer, and pancreatic cancer. Developed using the company's proprietary BiTAC platform, this candidate is designed to simultaneously bind to a tumor-associated antigen and the CD3 receptor on T-cells, thereby redirecting T-cell cytotoxicity to eliminate malignant cells. As of early 2024, the specific tumor-associated antigen targeted by VX-A903-1 has not been publicly disclosed, and the program remains in the discovery phase of development.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on VX-A903-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX-A903-1.

Explore the full profile